In addition, a pooled analysis of 11,317 patients with autoimmune diseases treated with the TNF inhibitor certolizumab pegol in clinical trials demonstrated that for patients with RA, lymphatic and haematopoietic cancer incidence (principally lymphoma) was increased compared with the age- and gender-matched GLOBOCAN/SEER general population (standardised IR: 2.1; 95% CI 1.2–3.6) [160]. The gene discussed is TNF; the disease is lymphoma.